Quarterly ResultAug 5, 2026, 05:29 PM
Vir Bio Q2 Net Income $80.08M; Revenue $238.95M
AI Summary
Vir Biotechnology reported a significant turnaround in Q2 2026, achieving a net income of $80.08 million, compared to a net loss of $110.96 million in the prior year. This was primarily driven by a substantial increase in license and collaboration revenue, which surged to $238.95 million. For the first half of 2026, the company significantly reduced its net loss to $45.62 million from $231.92 million in H1 2025. The company also completed a follow-on public offering, raising $162.2 million, and reported $1.01 billion in cash, cash equivalents, and investments as of June 30, 2026.
Key Highlights
- Q2 2026 net income was $80.08 million, a significant improvement from a $110.96 million net loss in Q2 2025.
- Q2 2026 total revenues surged to $238.95 million from $1.21 million in Q2 2025.
- Basic EPS for Q2 2026 was $0.48, up from $(0.80) in Q2 2025.
- Net cash used in operating activities for H1 2026 decreased to $9.06 million from $198.34 million in H1 2025.
- Completed a follow-on public offering in February 2026, generating $162.2 million in net proceeds.
- Cash, cash equivalents, and investments totaled $1.01 billion as of June 30, 2026.
- Total assets increased to $1.21 billion as of June 30, 2026, from $1.00 billion at year-end 2025.
Price Impact
More from VIR